Dermal Cumulative Irritant Patch Study
NCT04064125
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
FMX-101
Sponsor
Vyne Therapeutics Inc.